New ALS drug trial hopes to slow disease progression
NCT ID NCT07410806
First seen Jun 27, 2026 · Last updated Jul 21, 2026 · Updated 4 times
Summary
This clinical trial is testing an oral drug called NUZ-001 in 160 people with ALS. Participants take the drug or a placebo daily for 36 weeks. The study measures how the disease progresses using a scale of physical function and survival. The goal is to see if NUZ-001 can slow ALS and improve outcomes.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- NUZ-001 (oral drug)
- What this could lead to
- If successful, this could point toward a treatment that slows ALS progression and improves quality of life.
- What could go wrong
- This is an early-to-mid stage trial with only 160 participants. The drug may not slow the disease or could cause side effects like liver issues.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for AMYOTROPHIC LATERAL SCLEROSIS (ALS) are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Healey Center for ALS at Massachusetts General Hospital
Boston, Massachusetts, 02114, United States
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can a Custom-Made genetic drug slow ALS?
- Can a One-Time gene shot calm inflammation in ALS?
- Can filtering the blood slow ALS in people with a troubling antibody?
- Blood test may slash ALS diagnosis time from months to days
- Custom gene silencer takes aim at a rare form of ALS
- Could a gentle brain ZAP help ALS patients breathe easier?